Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant
about
Vaccine adjuvants as potential cancer immunotherapeuticsEnhancement of tumour-specific immune responses in vivo by 'MHC loading-enhancer' (MLE)Cancer/testis antigens, gametogenesis and cancerCharacterization of a cancer/testis (CT) antigen gene family capable of eliciting humoral response in cancer patientsIdentification and analysis of tumour-associated antigens in hepatocellular carcinoma.Anchor side chains of short peptide fragments trigger ligand-exchange of class II MHC moleculesMelanoma: tumor microenvironment and new treatments.Outlining novel cellular adjuvant products for therapeutic vaccines against cancer.NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses.A cancer vaccine induces expansion of NY-ESO-1-specific regulatory T cells in patients with advanced melanoma.Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients.Centrosomal localisation of the cancer/testis (CT) antigens NY-ESO-1 and MAGE-C1 is regulated by proteasome activity in tumour cellsExpression of the cancer testis antigen IGF2BP3 in colorectal cancers; IGF2BP3 holds promise as a specific immunotherapy target.Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1.Trial watch: Peptide vaccines in cancer therapyTSPY is a cancer testis antigen expressed in human hepatocellular carcinoma.NY-ESO-1 immunotherapy for multiple myeloma.Leukemia-associated antigens as target structures for a specific immunotherapy in chronic myeloid leukemia.Promising particle-based vaccines in cancer therapy.Systematic identification of immunodominant CD4+ T cell responses to HpaA in Helicobacter pylori infected individuals.Vaccine-induced antibody responses in patients with carcinoma.Hypoxia regulates the sperm associated antigen 4 (SPAG4) via HIF, which is expressed in renal clear cell carcinoma and promotes migration and invasion in vitro.NY-ESO-1 specific antibody and cellular responses in melanoma patients primed with NY-ESO-1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1 fowlpox virus.Identification of two new HLA-A*0201-restricted cytotoxic T lymphocyte epitopes from colorectal carcinoma-associated antigen PLAC1/CP1.Induction of CD8 T-cell responses restricted to multiple HLA class I alleles in a cancer patient by immunization with a 20-mer NY-ESO-1f (NY-ESO-1 91-110) peptide.Identification of a novel NY-ESO-1 promiscuous helper epitope presented by multiple MHC class II molecules found frequently in the Japanese population.Identification of new NY-ESO-1 epitopes recognized by CD4+ T cells and presented by HLA-DQ B1 03011.Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8+ and CD4+ T-cell responses with multiple specificities including a novel DR7-restricted epitope.Intranasal immunization with an epitope-based vaccine results in earlier protection, but not better protective efficacy, against Helicobacter pylori compared to subcutaneous immunization.SCIB2, an antibody DNA vaccine encoding NY-ESO-1 epitopes, induces potent antitumor immunity which is further enhanced by checkpoint blockade.Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™.New hypotheses for large-scale epigenome alterations in somatic cancer cells: a role for male germ-cell-specific regulators.Identification of Two Lpp20 CD4+ T Cell Epitopes in Helicobacter pylori-Infected Subjects.
P2860
Q26752522-E3764BFA-5840-497A-B1E3-97C4D727C4ECQ28476101-2720DD15-FA11-40EE-A90E-529943DBE269Q29616129-B9056323-CB03-4522-83C9-712111409594Q30358114-9FFE09BC-CB97-4783-8F36-1DB21DA75BAAQ33212678-49FC8616-96BD-46C6-A747-43D990318DBFQ33324394-8B8943BD-54F1-4FC6-9159-6C9A7A7408D8Q33675676-996A55E3-8F0F-4542-8627-F8A283243AA1Q33997622-0B02213D-A130-408A-B6B0-490BCA9922D2Q34388367-D6B60C59-2798-4EC2-AEF7-060FB0BD8575Q34461203-AFF9652D-6440-4AB8-903F-0AC37BEB6EE7Q35039508-9DC9DC17-8EA7-496C-919C-79F1F494E1F2Q35067995-4BBB65DF-0FD1-4F95-9CFB-21902ED516FEQ35863071-B51473AC-DD70-4F7A-B171-4C5A4745CCE7Q36471827-675C699B-7C31-4E4C-BB43-905E4D1B274DQ36476100-0F0E4DCC-8794-4955-A76C-73392B9C5E41Q36615203-2EB02E72-4378-43AB-866A-E67E3C5CB52FQ36637651-935649A6-6180-4A64-BA95-112F7EE67F27Q37088532-3FA7FF64-E72E-480A-8063-3C840868D4B0Q37259642-BDBCC72A-29A0-4A36-9E7E-60F7E301D036Q37688064-7F037A53-823E-4B4D-A620-BB3025E077ABQ37762272-231FCF40-7FAB-4C95-AC56-B863A471D59FQ39131858-243B92B6-23A3-4BC5-9145-A7860FACD050Q39150340-5A5F77AF-4E62-4C72-9FFB-B96540EF4DA4Q39162824-8E22CA64-7C86-4B62-8C43-5A3D8EABE476Q39325954-636479B4-B8DB-46EC-A6C2-6AC03E617AF7Q40135212-D0E61B30-08DB-4097-A8A3-19DF724C6641Q40375552-AF86D184-4CA3-4B9C-88CC-8EA8E89704C6Q40448718-ECC67610-FF94-40A4-ACEA-14C1DA8C8921Q41184340-B0542B87-A6A5-4743-8348-C0A11E3E234DQ41894814-BB0F0D7D-62CA-49CE-9782-30E9AC3B6AA2Q44545688-DA4D74F7-4003-4F9C-8632-83B097AE944DQ53306166-53EA2165-99A1-462B-8317-19208FA4FC44Q55545288-1770237A-6C05-424D-A45D-F86C84064A26
P2860
Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Immunodominant CD4+ responses ...... lated with ISCOMATRIX adjuvant
@ast
Immunodominant CD4+ responses ...... lated with ISCOMATRIX adjuvant
@en
type
label
Immunodominant CD4+ responses ...... lated with ISCOMATRIX adjuvant
@ast
Immunodominant CD4+ responses ...... lated with ISCOMATRIX adjuvant
@en
prefLabel
Immunodominant CD4+ responses ...... lated with ISCOMATRIX adjuvant
@ast
Immunodominant CD4+ responses ...... lated with ISCOMATRIX adjuvant
@en
P2093
P2860
P50
P356
P1476
Immunodominant CD4+ responses ...... lated with ISCOMATRIX adjuvant
@en
P2093
Eugene Maraskovsky
He-Cheng Zhu
Heather Goldie
Heather Jackson
Ian D Davis
Jonathan Cebon
Lena Miloradovic
Lloyd J Old
Mark Rizkalla
Nektaria Dimopoulos
P2860
P304
P356
10.1073/PNAS.0403271101
P407
P577
2004-06-14T00:00:00Z